CTI BioPharma Gross Profit

The latest gross profit for CTIC is $71M as of March 2023. That compares with $2M in the prior-year period — up 3435.4% year over year. That is below the Healthcare sector average of $66B. Investors often review this figure alongside CTI BioPharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTIC's gross profit moved from $2M to $71M — a 3435.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CTI BioPharma's operating scale or balance-sheet position.

Against Healthcare companies, CTIC currently prints $71M for gross profit, while the sector average sits near $66B. That is roughly 99.9% below the sector mean. Large gaps often invite a closer look at CTI BioPharma's growth, margins, and balance sheet.

A gross profit figure of $71M for CTIC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $66B. Explore the charts below for those layers of context.

After noting CTIC's gross profit ($71M), review year-over-year change from $2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.